Sorafenib inhibits tumor cell proliferation by blocking the RAS/Raf/MEK/ERK signaling pathway, and attenuates tumor angiogenesis by blocking the vascular endothelial growth factor receptor 2 pathway and platelet-derived growth factor receptors [60]. This evidence concerns the gene MAPK1 and neoplasm.